BTW
AMPH icon

Boston Trust Walden’s Amphastar Pharmaceuticals AMPH Stock Holding History

Boston Trust Walden’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-944,789
Closed -$18.5M – 397
2026
Q1 		$18.5M Sell
944,789
-142,477
-13% -$3.49M 0.15% 184
2025
Q4 		$29.1M Sell
1,087,266
-85,841
-7% -$2.21M 0.22% 158
2025
Q3 		$31.3M Sell
1,173,107
-3,346
-0.3% -$86.4K 0.23% 152
2025
Q2 		$27M Sell
1,176,453
-39,171
-3% -$972K 0.19% 164
2025
Q1 		$35.2M Buy
1,215,624
+236,704
+24% +$7.56M 0.26% 149
2024
Q4 		$36.3M Buy
978,920
+439,281
+81% +$20.1M 0.26% 150
2024
Q3 		$26.2M Buy
+539,639
New +$23.7M 0.18% 165

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Boston Trust Walden's AMPH Position: Q2 2026 in Review

Boston Trust Walden sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2026, closing a stake of 944,789 shares — an estimated $18.5M sold.

Boston Trust Walden first reported a position in AMPH in Q3 2024 and held it in 7 quarters. The position peaked at $36.3M in Q4 2024. 212 funds tracked by Wall St. Rank hold AMPH as of Q2 2026.

  • Boston Trust Walden reported no remaining Amphastar Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Boston Trust Walden sold 944,789 Amphastar Pharmaceuticals shares in Q2 2026, an estimated $18.5M.
  • Boston Trust Walden first reported a position in Amphastar Pharmaceuticals in Q3 2024 and held it in 7 quarters.
  • Boston Trust Walden's Amphastar Pharmaceuticals position peaked at $36.3M in Q4 2024.
  • 212 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2026.

Based on Boston Trust Walden's 13F filing for Q2 2026, filed 24 Jul 2026.